Consun Pharmaceutical Group Future Growth
Future criteria checks 3/6
Consun Pharmaceutical Group is forecast to grow earnings and revenue by 14.4% and 12.3% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 26% in 3 years.
Key information
14.4%
Earnings growth rate
13.7%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | 12.3% |
Future return on equity | 26.0% |
Analyst coverage | Low |
Last updated | 12 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,747 | 1,240 | N/A | N/A | 1 |
12/31/2025 | 3,364 | 1,044 | N/A | N/A | 2 |
12/31/2024 | 2,940 | 928 | N/A | N/A | 1 |
12/31/2023 | 2,590 | 785 | N/A | N/A | N/A |
9/30/2023 | 2,528 | 759 | N/A | N/A | N/A |
6/30/2023 | 2,466 | 734 | 828 | 869 | N/A |
3/31/2023 | 2,403 | 708 | 862 | 908 | N/A |
12/31/2022 | 2,340 | 683 | 896 | 948 | N/A |
9/30/2022 | 2,246 | 660 | 836 | 906 | N/A |
6/30/2022 | 2,152 | 636 | 776 | 865 | N/A |
3/31/2022 | 2,098 | 613 | 701 | 795 | N/A |
12/31/2021 | 2,045 | 590 | 627 | 726 | N/A |
9/30/2021 | 1,959 | 565 | 655 | 731 | N/A |
6/30/2021 | 1,874 | 541 | 683 | 737 | N/A |
3/31/2021 | 1,813 | 520 | 748 | 802 | N/A |
12/31/2020 | 1,753 | 499 | 813 | 867 | N/A |
9/30/2020 | 1,653 | 269 | 639 | 717 | N/A |
6/30/2020 | 1,553 | 39 | 465 | 567 | N/A |
3/31/2020 | 1,641 | 60 | 334 | 475 | N/A |
12/31/2019 | 1,728 | 80 | 203 | 383 | N/A |
9/30/2019 | 1,822 | 288 | 231 | 442 | N/A |
6/30/2019 | 1,916 | 496 | 259 | 501 | N/A |
3/31/2019 | 1,880 | 481 | 410 | 628 | N/A |
12/31/2018 | 1,844 | 465 | 561 | 754 | N/A |
9/30/2018 | 1,802 | 448 | 519 | 662 | N/A |
6/30/2018 | 1,760 | 430 | 476 | 570 | N/A |
3/31/2018 | 1,710 | 413 | 337 | 411 | N/A |
12/31/2017 | 1,660 | 396 | 197 | 252 | N/A |
9/30/2017 | 1,601 | 372 | N/A | 323 | N/A |
6/30/2017 | 1,541 | 347 | N/A | 393 | N/A |
3/31/2017 | 1,382 | 327 | N/A | 421 | N/A |
12/31/2016 | 1,223 | 308 | N/A | 449 | N/A |
9/30/2016 | 1,060 | 291 | N/A | 362 | N/A |
6/30/2016 | 896 | 274 | N/A | 275 | N/A |
3/31/2016 | 863 | 262 | N/A | 230 | N/A |
12/31/2015 | 831 | 250 | N/A | 184 | N/A |
9/30/2015 | 814 | 246 | N/A | 180 | N/A |
6/30/2015 | 798 | 242 | N/A | 175 | N/A |
3/31/2015 | 764 | 226 | N/A | 235 | N/A |
12/31/2014 | 731 | 211 | N/A | 295 | N/A |
9/30/2014 | 697 | 198 | N/A | 285 | N/A |
6/30/2014 | 664 | 185 | N/A | 275 | N/A |
3/31/2014 | 618 | 169 | N/A | 219 | N/A |
12/31/2013 | 572 | 153 | N/A | 164 | N/A |
9/30/2013 | 538 | 144 | N/A | 118 | N/A |
6/30/2013 | 504 | 135 | N/A | 72 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C1P's forecast earnings growth (14.4% per year) is above the savings rate (0.6%).
Earnings vs Market: C1P's earnings (14.4% per year) are forecast to grow slower than the German market (15.1% per year).
High Growth Earnings: C1P's earnings are forecast to grow, but not significantly.
Revenue vs Market: C1P's revenue (12.3% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: C1P's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: C1P's Return on Equity is forecast to be high in 3 years time (26%)